(3S,8S,9S,10R,13R,14S,17R)-17-((R)-6-hydroxy-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11-2,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren | 1221974-07-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (3S,8S,9S,10R,13R,14S,17R)-17-((R)-6-hydroxy-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11-2,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren
• 英文别名: cholesterol^[25]；25R-cholesterol；25-Cholesterol；(6R)-6-[(8S,9S,10R,13R,14S,17R)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptan-2-ol
• CAS: 1221974-07-7
• 化学式: C₂₇H₄₆O
• 分子量: 386.662
• InChiKey: LNUKMRYBAPMWBV-HZPUXBNGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.3
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  在 水 、 sodium iodide 、 锌 作用下， 以 乙二醇二甲醚 为溶剂， 生成 (3S,8S,9S,10R,13R,14S,17R)-17-((R)-6-hydroxy-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11-2,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren
  参考文献：
  名称：

  胆固醇冷凝效应的颠倒看法：表面占有率是否起作用？

  摘要：

  胆固醇的缩合作用已与羟基位于 C-25 位（即 25-OH'）的结构异构体的缩合作用进行了比较，即，有利于脂质膜中“倒置”取向的异构体。由 1,2-二肉豆蔻酰基-sn-甘油-3-磷酸胆碱 (DMPC)/胆固醇和 DMPC/25-OH'制成的混合单层的表面压力 - 面积等温线表明，25-OH' 的冷凝作用比胆固醇弱。由 1,2-二棕榈酰-sn-甘油-3-磷酸胆碱 (DPPC)制成的脂质体的最近邻识别测量也表明，25-OH' 在生理相关的流体双层状态下具有较弱的冷凝作用。这些发现为表面占有率在胆固醇的凝聚作用中发挥作用提供了支持。

  DOI：

  10.1021/la100878s

文献信息

• Methods of testing for bronchial asthma or chronic obstructive pulmonary disease
  申请人：Ohtani Noriko

  公开号：US20050208496A1

  公开（公告）日：2005-09-22

  An objective of the present invention is to provide a method of testing for bronchial asthma or chronic obstructive pulmonary disease, a method of screening for candidate compounds for treating bronchial asthma or chronic obstructive pulmonary disease, and a pharmaceutical agent for treating bronchial asthma or chronic obstructive pulmonary disease. The present invention identified genes whose expression levels varied between respiratory epithelial cells that had been stimulated by IL-13 to induce the goblet cell differentiation, and unstimulated respiratory epithelial cells. The respiratory epithelial cells were cultured according to the air interface method. The genes were revealed to be useful as markers for testing for bronchial asthma or chronic obstructive pulmonary disease and screening for therapeutic agents for such diseases. Specifically, the present invention provides methods of testing for bronchial asthma or chronic obstructive pulmonary disease and methods of screening for compounds to treat the diseases based on the comparison of the expression levels of marker genes identified as described above.

  本发明的目标是提供一种用于检测支气管哮喘或慢性阻塞性肺疾病的方法，一种筛选治疗支气管哮喘或慢性阻塞性肺疾病候选化合物的方法，以及一种治疗支气管哮喘或慢性阻塞性肺疾病的药物。本发明确定了基因，这些基因的表达水平在通过IL-13刺激诱导粘液细胞分化的呼吸上皮细胞和未受刺激的呼吸上皮细胞之间有所变化。呼吸上皮细胞是根据空气界面方法培养的。这些基因被发现可用作检测支气管哮喘或慢性阻塞性肺疾病的标记物和筛选治疗这些疾病的治疗剂的标记物。具体而言，本发明提供了一种基于上述描述的标记基因的表达水平比较的方法，用于检测支气管哮喘或慢性阻塞性肺疾病和筛选治疗该疾病的化合物的方法。
• Methods for subtyping of lung adenocarcinoma
  申请人：GeneCentric Therapeutics, Inc.

  公开号：US10934595B2

  公开（公告）日：2021-03-02

  Methods and compositions are provided for determining a subtype of lung adenocarcinoma (AD) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung adenocarcinoma. Also provided herein are methods and compositions for determining the response of an individual with an adenocarcinoma subtype to a therapy such as immunotherapy.

  本文提供了通过检测选自一组肺腺癌基因特征的至少一种分类生物标记物的表达水平来确定个体的肺腺癌亚型的方法和组合物。本文还提供了用于确定腺癌亚型个体对免疫疗法等疗法的反应的方法和组合物。
• Methods for subtyping of lung squamous cell carcinoma
  申请人：GeneCentric Therapeutics, Inc.

  公开号：US11041214B2

  公开（公告）日：2021-06-22

  Methods and compositions are provided for determining a subtype of lung squamous cell carcinoma (SQ) of an individual by detecting the expression level of at least one classifier biomarker selected from a group of gene signatures for lung squamous cell carcinoma. Also provided herein are methods and compositions for determining the response of an individual with a squamous cell carcinoma subtype to a therapy such as immunotherapy.

  本文提供了通过检测选自肺鳞状细胞癌基因特征组的至少一种分类生物标志物的表达水平来确定个体的肺鳞状细胞癌亚型的方法和组合物。本文还提供了用于确定鳞状细胞癌亚型个体对免疫疗法等疗法的反应的方法和组合物。
• Tools for diagnostics, molecular definition and therapy development for chronic inflammatory joint diseases
  申请人：Haeupl Thomas

  公开号：US20060204968A1

  公开（公告）日：2006-09-14

  The invention relates to tools for the diagnosis, molecular definition and development of treatment of chronic inflammatory joint diseases and other inflammatory, infectious or tumourous diseases. According to the invention, genome data (genomics), proteome data (proteomics) and immunome data (immunomics) are used in the analysis and development of treatment of chronic joint diseases. The invention is based on the use of gene sequences and derived mRNAs and proteins, in addition to antibodies having a specific nature for the derived proteins, for characterising inflammatory and non-inflammatory rheumatic joint diseases, auto-immune diseases and infectious diseases. Etiologically significant pathogenicity principles of chronic inflammatory joint diseases which have been unclear until now can be derived from the examinations carried out. Furthermore, interpretation algorithms can be created for the classification, prognosis evaluation and treatment optimisation of said joint diseases, and new strategies for treatment and points of attack for medicaments can be derived.
• METHOD TO IDENTIFY A NOVEL CLASS OF IMMUNOLOGIC ADJUVANTS
  申请人：COWING CAROL O.

  公开号：US20120258125A1

  公开（公告）日：2012-10-11

  Methods of identifying an adjuvant capable of activating dendritic cells including measuring expression level genes in skin of an animal prior to exposure to a test compound, wherein the genes are known to be upregulated or downregulated in the skin of the animal in response to topical application of dibutyl phthalate (DBP) to skin of said animal; exposing skin of an animal of the same species to the test compound; measuring expression level of the genes in the skin of the animal after exposure to the test compound; and comparing expression level of the genes measured before and after exposure to the test compound, wherein an increase or decrease in expression level of the genes following exposure to the test compound indicates that the test compound is capable of activating dendritic cells. Also included are compositions that induce dendritic cell migration and modulate expression level of genes in skin cells.